1Terada N,Lucas JJ,Szepesi A,et al.Rapamycin blocks cell cycle progression of activated T cell prior to events characteristic of the middle to late G1 phase of the cycle [J].J Cell Physiol,1993,154(1): 7-15.
7Huang S,Houghton PJ.Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic[J].Curr Opin Investig Drugs,2002,3(2):295-304.
8Chen F,Ornasa M,Kondo N,et al.Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation[J].Ann Thorac Surg,2009,87(1):6-7.
9Hay N,Sonenberg N.Upstream and downstream of mTOR[J].Genes Dev,2004,18(16): 1 926-1 945.
10Vignot S,Faivre S,Aguirre D,et al.mTOR-targeted therapy of cancer with rapamycin derivatives[J].Ann Oncol,2005,16(4):525-537.
5Yamanaka K, Mizutani H. The role of cytokines/chemokines in the pathogenesis of atopic dermatitis [ J ]. Curr Probl Dermatol, 2011, 41 : 80-92.
6Harada D, Takada C, Nosaka Y, et ol. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models[J]. Int lmmunopharmacol, 2009, 9( 1 ) : 55-62.
7Lee JI-I, Jung KM, Bae II-I, et al. Anti-inflammatory and barrier pro- tecting effect of lithospermum erythrorhizon extracts in chronic ox- azolone-induced murine atopic dermatitis[ J]. J Dermatol Sci, 2009, 56 ( 1 ) : 64-66.
8Alyoussef A. Arjunolie acid protects ag,iinst DNCB-indueed atopic dermatitis-like symptoms in mice by restoring a normal cytokine bal- ance[J]. Eur Cytokine Netw, 2015, 26(2) : 38-45.
9Spilman P, Podlutskaya N, Hart MJ,et al. Inhibition of mTOR by rapamycin abblishes cognitive deficits and reduces amyloid-beta levels in amouse model of Alzheimer' s disease [ J ]. PLoS One, 2010, 5 (4) : e9979.
10Emami S, Valizadeh H, Islambulchilar Z, et al. Development and Physicochemical Characterization of Sirolimus Solid Dispersions Prepared by Solvent Evaporation Method[ J], Adv Pharm Bull, 2014, 4 (4) : 369-374.
